https://scholars.lib.ntu.edu.tw/handle/123456789/518153
標題: | A drug safety evaluation of risankizumab for psoriasis | 作者: | Huang Y.-W. TSEN-FANG TSAI |
關鍵字: | Interleukin-23A; psoriasis; risankizumab; safety | 公開日期: | 2020 | 出版社: | Taylor and Francis Ltd | 卷: | 19 | 期: | 4 | 起(迄)頁: | 395-402 | 來源出版物: | Expert Opinion on Drug Safety | 摘要: | Introduction: Risankizumab is a fully human monoclonal antibody that selectively targets interleukin (IL)-23A, interfering with the IL-23/17 axis that plays a crucial role in keratinocyte proliferation. In 2019, risankizumab was approved globally for the treatment of moderate-to-severe psoriasis. Areas covered: The safety profile of risankizumab for the treatment of psoriasis is assessed in this review. A literature search was performed on 18 October 2019, and additional data from pooled safety analyses were evaluated. Expert opinion: Drugs blocking the IL-23 pathway are the most recently approved treatment for psoriasis, and risankizumab seems to be the most effective one among the three IL-23 blockers approved. Risankizumab was generally well tolerated in the clinical trials and was found to be relatively safe. The safety profile of risankizumab is generally similar in clinical trials compared to adalimumab and ustekinumab. In a subset of patients with latent tuberculosis, no active tuberculosis developed after risankizumab treatment for 55?weeks without tuberculosis prophylaxis. The combination of safety, efficacy and less frequent injection (every 12?weeks) make risankizumab an attractive new choice for individuals with moderate-to-severe psoriasis. However, the long-term impact of anti-drug antibodies (24%) observed in pivotal studies as well as safety concerns in those with viral infections, hepatitis, malignancies and those in endemic tuberculosis areas, await further studies. ? 2020, ? 2020 Informa UK Limited, trading as Taylor & Francis Group. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081263338&doi=10.1080%2f14740338.2020.1736034&partnerID=40&md5=78f34fb39d8c1e81643d3fa78e941f1c https://scholars.lib.ntu.edu.tw/handle/123456789/518153 |
ISSN: | 1474-0338 | DOI: | 10.1080/14740338.2020.1736034 | SDG/關鍵字: | adalimumab; drug antibody; fumaric acid; isoniazid; neutralizing antibody; placebo; risankizumab; ustekinumab; dermatological agent; IL23A protein, human; interleukin 23p19; monoclonal antibody; risankizumab; acute heart infarction; adenocarcinoma; anaphylaxis; anus cancer; arthralgia; Article; basal cell carcinoma; bipolar disorder; bladder cancer; Bowen disease; breast cancer; breast carcinoma; cellulitis; congestive heart failure; depression; disease severity; drug efficacy; drug hypersensitivity; drug safety; drug tolerability; drug tolerance; epilepsy; erythema multiforme; esophagus carcinoma; gallbladder cancer; headache; heart arrest; hematoma; herpes zoster; human; infection; injection site bleeding; injection site contusion; injection site erythema; injection site pain; injection site pruritus; injection site reaction; injection site swelling; intestine carcinoma; liver metastasis; lymph node metastasis; malignant neoplasm; medical literature; melanoma; multiple myeloma; non melanoma skin cancer; opportunistic infection; osteomyelitis; pancreatitis; phase 1 clinical trial (topic); phase 2 clinical trial; phase 3 clinical trial (topic); prostate cancer; psoriasis; psoriasis vulgaris; randomized controlled trial (topic); rectum cancer; rhinopharyngitis; sepsis; squamous cell carcinoma; squamous cell skin carcinoma; stomach cancer; stomach perforation; suicidal ideation; suicide attempt; upper respiratory tract infection; animal; complication; drug administration; immunology; latent tuberculosis; pathology; severity of illness index; time factor; Animals; Antibodies, Monoclonal; Dermatologic Agents; Drug Administration Schedule; Humans; Interleukin-23 Subunit p19; Latent Tuberculosis; Psoriasis; Severity of Illness Index; Time Factors |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。